Skip to main content
. Author manuscript; available in PMC: 2013 Oct 1.
Published in final edited form as: J Psychopharmacol. 2012 Jul 11;26(10):1333–1347. doi: 10.1177/0269881112450786

Figure 2. CP 55,940-induced increased membrane-associated expression of 5-HT2A and D2 receptors in rat PFCx.

Figure 2

(A) Increased membrane-associated D2S receptor protein levels in PFCx of CP 55,940 treated rats. (**p<0.01 significant effect of CP 55,940 treatment compared to vehicle-treated controls). (B) Increased membrane-associated D2L receptor protein levels in PFCx of CP 55,940 treated rats. (**p<0.01 significant effect of CP 55,940 treatment compared to vehicle-treated controls). (C) Increased membrane-associated 5-HT2A receptor protein levels in PFCx of CP 55,940 treated rats. (*p<0.05 significant effect of CP 55,940 treatment compared to vehicle-treated controls). (D) Increased 5-HT2A receptor mRNA levels and reduced D2 receptor mRNA levels in PFCx of CP 55,940 treat rats. (*p<0.05 significant effect of CP 55,940 treatment compared to vehicle-treated controls). (E) Increased 5-HT2A receptor mRNA levels in CP 55,940 or GP 1a treated cells (**p<0.01 significant effect of CP 55,490 or GP 1a treatment compared to vehicle-treated controls) and reduced D2 receptor mRNA levels in CP 55,940 or ACEA treated cells (*p<0.05 significant effect of CP 55,940 or ACEA treatment compared to vehicle-treated controls). (F) AM 630 pretreatment prevents GP 1a and JWH 133-induced increases in 5-HT2A receptor mRNA. **p<0.01, significant effect of GP 1a or JWH 133 treatment on 5-HT2A receptor mRNA levels compared to vehicle-treated controls. ##p<0.01, significant effect of AM 630 pretreatment on the GP 1a or JWH 133-induced upregulation of 5-HT2A receptors. Representative Western blots are shown in this figure and IOD was calculated as described in Experimental Procedures. The data represent mean ± SEM (n=6–8).